Chemical Business Newsbase articles from September 2009

Chemical Business Newsbase archives from September 2009

Nagarjuna Fert revamps operations, scales up capacity.
September 30, 2009... Kakinada-based Nagarjuna Fertilisers and Chemicals Ltd has invested Rup 200 crores to hike its production capacity from the present 11.95 lakh tonnes/y to 15.66 lakh tonnes/y. The increase in capacity has been achieved through de-bottlenecking....

Wacker exits from solar wafer business.
September 30, 2009... On 30 Sep 2009, Wacker Chemie AG announced its exit from the solar wafer business and will transfer its shares in its joint venture Wacker Schott Solar GmbH (WSS) to its former partner Schott Solar AG. Wacker and Schott Solar have reached...

New film blames drug firm for plight of honey bees.
September 30, 2009... Vanishing of the Bees, which will be released in Britain in Oct 2009, claims the cause is the use of a new generation of pesticides that weakens the bees and makes them more susceptible to other diseases. The 90-minute film tells the story of...

Cancer jab girl had health problem: post-mortem results show schoolgirl had a serious underlying medical condition.
September 30, 2009... The girl who died on 29 Sep 2009 after a cervical cancer vaccine had a "serious underlying medical condition", it has emerged. Dr Caron Grainger, joint director of public health for NHS Coventry said in a statement: "Preliminary post-mortem...

Cosmetics sector under strain from slow sales, EU law, and pressure on innovations.
September 30, 2009... At its 2nd Cosmetics Symposium, Akadamie Fresenius has given tips for dealing with the new challenges: the cosmetics market is difficult and hard-fought. Sales are stagnating and tighter safety regulations from Brussels threaten to slow down...

Newly adopted Marketing Authorisation Decisions (28 Sep 2009): Clopidogrel Acino Pharma Film Coated Tablet.
September 30, 2009... On 30 Sep 2009 the European Commission (EC) announced decision number C(2009)7558 of 28 Sep 2009, the approval of EU/1/09/549 for Clopidogrel Acino Pharma Film Coated Tablet. The product contains clopidogrel at 75mg (seven package sizes) and is...

Newly adopted Marketing Authorisation Decisions (28 Sep 2009): Zyllt (film-coated tablet - oral use).
September 30, 2009... On 30 Sep 2009 the European Commission (EC) announced decision number C(2009)7559 of28 Sep 2009, the approval of EU/1/09/553 for Zyllt (film-coated tablet - oral use). The product contains clopidogrel at 75mg (ten package sizes) and is indicated...

Threshold Pharmaceuticals Inc announces private equity financing of $35 M.
September 30, 2009... Threshold Pharmaceuticals Inc has entered into a securities purchase agreement with a select group of new investors that includes Federated Kaufmann Fund (Federated), Frazier Healthcare Ventures and Great Point Partners LLC plus several of the...

Discovery Laboratories says FDA agrees on lung drug programme.
September 30, 2009... Discovery Laboratories Inc held a teleconference on 29 Sep 2009 with the US Food and Drug Administration (FDA). The meeting established an approach to potentially resolve the remaining primary issue that Discovery Laboratories must address to...

Capstone Therapeutics announces completion of enrolment for second of two AZX100 Phase II studies in keloid ccarring.
September 30, 2009... Capstone Therapeutics (Capstone) announced the completion of enrolment for the second of its two ongoing AZX100 Phase II clinical trials in keloid scarring. The company also announced that its AZX100 Phase II clinical trial in trocar site...

Xoma presents results demonstrating novel mechanism of action for Xoma 052 in regulating IL-1 beta levels.
September 30, 2009... Xoma Ltd announced new data demonstrating the unique regulatory mechanism of action of Xoma 052, a potent antibody drug candidate that inhibits the inflammatory cytokine interleukin-1 beta (IL-1 beta). Xoma 052 is currently under study for the...

Hana Biosciences enters into Clinical Trial Agreement with the National Cancer Institute for development of Marqibo in paediatric cancer.
September 30, 2009... Hana Biosciences has entered into a Clinical Trial Agreement (CTA) with the Centre for Cancer Research (CCR) at the National Cancer Institute (NCI) for the co-development of Marqibo (vincristine sulfate liposomes injection) in refractory...

Armed Forces Radiobiology Research Institute (AFRRI) and Cleveland Biolabs Inc (CBLI) awarded grant from department of defence to study radioprotective effects of Protectan CBLB600 series.
September 30, 2009... Cleveland BioLabs Inc announced that the Joint Science and Technology Office for Chemical and Biological Defense at the Defense Threat Reduction Agency of the Department of Defense awarded the Armed Forces Radiobiology Research Institute (AFRRI)...

The Medicines Co licenses innovative new formulation of Argatroban; gains strategic complement to Angiomax franchise and potential near term revenue opportunity.
September 30, 2009... The Medicines Co announced that it has entered into a licence agreement with Eagle Pharmaceuticals Inc (Eagle) under which The Medicines Company will have rights in the US and Canada to a ready-to-use formulation of Argatroban, which is...

Abbott and Eisai submit application for approval of Humira for the treatment of Crohn's disease in Japan.
September 30, 2009... Abbott Japan Co Ltd (Abbott) and Eisai Co Ltd announced that they had submitted an application for approval of Crohn's disease as an additional indication for Humira (adalimumab), a fully human monoclonal anti-TNF-alpha antibody jointly...

Crucell NV strengthens its vaccine sales in the UK with a dedicated marketing and sales organization.
September 30, 2009... Dutch biopharma company Crucell NV announced the launch of its own dedicated marketing and sales organization in the United Kingdom by acquiring an experienced team, to further strengthen its vaccine sales position in one of the largest vaccine...

Wyeth Pharmaceuticals initiates Phase II and pays Ablynx another milestone of $4 M in the Tnf-Alpha Nanobody collaboration.
September 30, 2009... Ablynx has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $4 M has been triggered by the initiation by Wyeth of a first Phase II multiple dose study in...

Bioo Scientific Corp awarded USDA grant for development of technology to detect food contaminants.
September 30, 2009... The safety of the public food supply is an important global public health issue. In 2008, over 300,000 people were hospitalized with food poisoning in the US alone. Because of recent food contamination incidents, Congress just passed a sweeping...

Lipoxen appointed lead for vaccine programme grant.
September 30, 2009... Lipoxen plc announced that the Technology Strategy Board, the Government organisation charged with driving UK innovation, has appointed Lipoxen as lead member of the grant consortium for its controlled-release nanoparticle vaccine research...

Bharat Biotech's Anti-Staphylococcal Molecule Lysostaphin secures patent rights; could become drug of choice for treating life threatening S aureus bacteremia.
September 30, 2009... Bharat Biotech International (BBIL) announced its Anti-Staphylococcal Molecule Lysostaphin has secured patent rights in US, Europe, China, Australia including other nations. Lysostaphin is a potent anti-Staphylococcal therapeutic with a targeted...

Proteome Sciences plc: Results 1H ended Jun 2009.
September 30, 2009... Proteome Sciences plc, a leading developer of biomarkers in diagnostics and drug development, announced its interim results for 1H ended Jun 2009. The main events of the period are summarised: TMT sublicence signed between Thermo Fisher and Life...

Beckman Coulter Inc expands reproductive menu with sex hormone binding globulin assay.
September 30, 2009... Beckman Coulter expands its menu for reproductive disease state management with the introduction of the Access Sex Hormone Binding Globulin (SHBG) assay for use in the differential diagnosis of conditions of chronic or excessive androgenic...

Quotient BioResearch supports key industry trend with comprehensive biomarker services for drug development.
September 30, 2009... Quotient Bioresearch (Quotient) offers valuable know-how in marker development, the establishment and validation of methods, and routine quantification of close to 250 different biomarkers. The company has one of the largest and best equipped...

Quotient BioResearch delivers new insight into safety and efficacy of cardiovascular, diabetes and obesity drugs.
September 30, 2009... Data from Quotient Bioresearch's new extended lipid marker screen for assessing drug safety and efficacy was presented at the Institute of Biomedical Sciences (IBMS) annual congress in Birmingham (UK). The range of markers included in the rapid...

ImmuCell's mastitis drug meets pivotal effectiveness study end point.
September 30, 2009... ImmuCell Corp announced initial results from its pivotal effectiveness study of Mast Out. All data, results and conclusions discussed in this press release are subject to review and approval by the US Food and Drug Administration (FDA), Center...

Nabi Biopharmaceuticals land $10 M for smoking cessation trials.
September 30, 2009... Nabi Biopharmaceuticals (Nabi) has received $10 M in federal stimulus funding to start running its first late-stage human clinical trials on a smoking cessation vaccine, even as it continues to search for a partner or buyer for the product. The...

Dr Reddy's voluntarily recalls some products from US.
September 30, 2009... Dr Reddy's Laboratories Ltd (Dr Reddy's) is voluntarily recalling four products from the US market as a precaution as some lots contained oversized tablets. Dr Reddy's is recalling citalopram 40 mg in bottles of 100 tablets, fexofenadine 180 mg...

Biopharm Executive: Vivus - Savior of the pharma industry.
September 30, 2009... Obesity took centre stage in Sep 2009, with important clinical results released on two key products: Vivus Pharmaceuticals' Qnexa and Arena Pharmaceuticals' Lorcaserin. That follows the release of Phase III results on Orexigen's Contrave,...

Talecris Biotherapeutics prices initial public offering of common stock at $19/share.
September 30, 2009... Talecris Biotherapeutics Holdings Corp (Talecris Biotherapeutics) announced the pricing of its initial public offering of 50 M shares of its common stock at a price of $19/share. Of the shares being offered, 28,947,368 are being offered by the...

Celldex and CuraGen stockholders approve acquisition of CuraGen Corp.
September 30, 2009... Celldex Therapeutics Inc (Celldex) and CuraGen Corp announced that, at special meetings held earlier on 30 Sep 2009, Celldex's stockholders approved the issuance of shares of Celldex common stock pursuant to the previously disclosed Agreement...

BioSante Pharmaceuticals and Cell Genesys announce approval of merger by BioSante stockholders and adjournment of Cell Genesys stockholders meeting until 14 Oct 2009.
September 30, 2009... BioSante Pharmaceuticals Inc and Cell Genesys Inc announced that BioSante stockholders have approved the merger between the two companies with BioSante as the surviving company. Ninety percent of the Cell Genesys shares voted to date have been...

Vertex Pharmaceuticals to receive $155 M in cash related to future telaprevir milestone payments.
September 30, 2009... Vertex Pharmaceuticals Inc (Vertex) will receive $155 M in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 M in cash for the issuance of notes repayable no later than 31 Oct 2012 in the...

Incyte announces closing of public offering of common stock.
September 30, 2009... Incyte Corp announced the closing of its public offering of 20.7 M shares of its common stock at a price to the public of $6.75/share, which includes 2.7 M shares sold upon exercise by the underwriters of their option to purchase additional...

Ascent Solar announces public offering of common stock and commitment from Norsk Hydro to purchase common stock.
September 30, 2009... Ascent Solar Technologies Inc (Ascent Solar) intends to commence an underwritten public offering of 4 M shares of its common stock. The offering is being conducted pursuant to an effective shelf registration statement on file with the Securities...

Pozen Inc announces Federal District Court grants motion to dismiss securities class action lawsuit.
September 30, 2009... Pozen Inc announced that on 29 Sep 2009, the US District Court for the Middle District of North Carolina granted the company's motion to dismiss a consolidated class action lawsuit against the company, its chief executive officer and certain of...

Bioheart makes breakthrough in cardiovascular therapy with stem cells obtained from fat tissue.
September 30, 2009... Bioheart Inc offers yet another medical breakthrough with the next-level stem cell treatment for cardiac patients. The stem cells aid in limiting damage due to a cardiac event and promote angiogenesis or formation of new blood vessels. Bioheart,...

Meridian Bioscience Europe announces agreement to distribute test for GI disease.
September 30, 2009... Meridian Bioscience Inc announced that Meridian Bioscience Europe srl (Meridian) has signed an agreement with Buhlmann Laboratories AG for distribution in Italy of an innovative test for inflammatory conditions of the intestine, Quantum Blue...

Levi & Korsinsky LLP investigates possible breach of fiduciary duty by board of CombinatoRx Inc.
September 30, 2009... Levi & Korsinsky is investigating the Board of Directors of CombinatoRx Inc for possible breaches of fiduciary duty and other violations of state law in connection with an announced merger with Neuromed Pharmaceuticals Inc (Neuromed), a...

Can-Fite initiates preparatory work for psoriasis Phase III trial with CF101.
September 30, 2009... Can-Fite BioPharma Ltd (Can-Fite) announced the initiation of preparatory work for a Phase III trial with CF101 in psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with...

Mitsubishi Electric to enter North American photovoltaic inverter market for large-scale solar power generation systems.
September 30, 2009... Mitsubishi Electric Corp (Mitsubishi) will introduce two photovoltaic inverters to the North American market, with the 100 KW model scheduled for launch in Oct 2010 and the 250 KW model scheduled in Apr 2011. This will make the company the first...

VeriChip Corp announces Phase II development of in vivo glucose-sensing RFID microchip with Receptors LLC.
September 30, 2009... VeriChip Corp and its development partner Receptors LLC that VeriChip plans to fund its existing development partnership with Receptors to launch Phase II development of an in vivo glucose-sensing RFID microchip. In Phase II of this programme,...

NIAID to fund development of Emergent BioSolutions' advanced anthrax vaccine candidate.
September 30, 2009... Emergent BioSolutions Inc (Emergent) was awarded a cooperative agreement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to further the development of one of Emergent's advanced...

ImmunoCellular Therapeutics' antibody shows promise in detecting pancreatic and lung cancer in serum test.
September 30, 2009... ImmunoCellular Therapeutics Ltd announced results from its pilot study evaluating the cancer detection abilities of one of its lead monoclonal antibody product candidates, ICT-109. Data from this study demonstrated that ICT-109 had a...

Aphios awarded NIH ARRA Challenge grant for pathogen inactivation technology for blood products.
September 30, 2009... Aphios Corp has been awarded a RC-1 Challenge grant (No 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health's (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a...

Expression Analysis announces new grant initiative.
September 30, 2009... Expression Analysis Inc announced a family of grants focused on one unifying purpose: To accelerate research into complex diseases and aid researchers in unlocking biological mysteries. Dedicated to a deeper understanding of human health and...

New study in the Journal Paediatrics reports results showing superior efficacy of spinosad head lice treatment as compared to permethrin.
September 30, 2009... ParaPRO LLC announced the results of two Phase III clinical studies published online in Sep 2009 in the journal Paediatrics which concluded that a spinosad suspension was significantly more effective in eliminating head lice (pediculosis...

FASgen receives new $1.4 M NIH grant for obesity research.
September 30, 2009... FASgen Inc is pleased to announce that it was awarded a new $1.4 M SBIR Phase II NIH grant for continued research for obesity. FASgen has for some time had extensive research into the effects of inhibition of the fatty acid biosynthesis pathway...

Pfizer receives approval from Australian Competition And Consumer Commission (ACCC) for pending acquisition of Wyeth.
September 30, 2009... Pfizer Inc announced that the Australian Competition and Consumer Commission (ACCC) has approved the company's pending acquisition of Wyeth. The ACCC's decision includes Pfizer's commitment to divest certain animal health assets in Australia....

Starwood Solar I agreement terminated.
September 30, 2009... APS announced it has received notice from Starwood Energy Group Global LLC (Starwood) that it is terminating the long-term purchase power agreement the two companies signed in May 2009. This ends plans for Starwood Solar I, the 290-megawatt...

enXco and Carrier Clinic break ground on a 1.8 MW solar project.
September 30, 2009... enXco, an EDF Energies Nouvelles Company, and Carrier Clinic conducted a ground-breaking ceremony to mark the beginning of construction of the 1.8 megawatt (DC) solar photovoltaic array. The ground-mount fixed tilt solar array, utilizing First...

Quaker Chemical Corporation announces quarterly dividend.
September 30, 2009... The Board of Directors of Quaker Chemical Corporation declared a quarterly dividend of $0.23 per share, payable on 30 Oct 2009, to shareholders of record at the close of business on 16 Oct 2009. Quaker Chemical Corporation is a leading global...

Dalian Shipyard places second order from Exousia's Chinese facility.
September 30, 2009... Exousia Advanced Materials Inc announced that China's largest shipyard, Dalian Shipyard, has placed a follow-up order to its initial order of zinc rich primers. The CEO of Exousia stated that Dalian Shipyard has followed up its initial order of...

Air Products supplies Nitrogen to NexPower's new PV facility in Taiwan.
September 30, 2009... Air Products announced it has signed, through its subsidiary Air Products San Fu Co Ltd in Taiwan, a long-term contract to provide nitrogen to NexPower Technology Corporation (NexPower), at its new thin-film photovoltaic (PV) facility in the...

Dow completes divestiture of ownership in Optimal Group of Companies for $660 M.
September 30, 2009... Union Carbide Corporation, a wholly owned subsidiary of The Dow Chemical company, has completed the divestiture of its ownership in the Optimal Group of Companies (Optimal) to Petroliam Nasional Berhad (Petronas) for an equity value of $660 M....

Zeus: Dedicated to advancing biomaterial technology with enhanced capabilities.
September 30, 2009... Zeus Inc announces its new state-of-the-art advanced materials laboratory dedicated exclusively to the extrusion, analysis, and characterization of Absorv Bioabsorbables. Zeus has also expanded its Absorv Bioabsorbables capabilities, including...

Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt.
September 30, 2009... Labopharm Inc (Labopharm) announced it has received notice from Sun Pharma Global FZE (Sun) advising that Sun has submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration for approval to market 100 mg, 200 mg...

Gevo launches development company to retrofit ethanol plants to make biobutanol.
September 30, 2009... Gevo announced the formation of Gevo Development LLC to develop a fleet of biorefineries based on retrofitting existing ethanol plants with Gevo's proprietary technology to produce biobutanol. Biobutanol is an advanced biofuel that can be...

Gevo announces first retrofit of ethanol demonstration plant to biobutanol for the oil and chemical industries.
September 30, 2009... Gevo Inc on 30 Sep 2009 announced the start up of the first biobutanol demonstration plant in the world designed from retrofitting an existing demonstration scale ethanol plant to produce biobutanol. In successfully producing biobutanol at the 1...

Differentiation and product performance are key strategies in the promising engineering plastics market in Latin America, finds Frost & Sullivan.
September 30, 2009... Sustained growth in the industrial sector and the growing utilization of high-performance plastics in some applications are the major factors driving the Latin American engineering plastics market. Plastics are cost-effective, versatile, and...

ICS secures private placement of 1 M units.
September 30, 2009... ICS Copper Systems Ltd has arranged a non-brokered private placement of 1 M units at a price of $0.10/unit for gross proceeds of $100,000. Each unit will consist of one common share and one full warrant entitling the holder to purchase a common...

BioFuel amends Credit Agreement and converts construction loans.
September 30, 2009... BioFuel Energy Corp announced that its operating subsidiaries have amended their secured Credit Agreement with BNP Paribas and a group of lenders, settling all outstanding issues among the parties and lifting all defaults previously asserted by...

AlphaRx and Riso Pharma sign collaboration and licensing agreement.
September 30, 2009... AlphaRx Inc has entered into an exclusive collaboration and licensing agreement with Riso Pharma Tech (Riso) for the development of ARX606T, an early stage product candidate intended for wound treatment. Under the terms of the agreement, AlphaRx...

Trina Solar signs sales agreement with Kerself SpA.
September 30, 2009... Trina Solar Ltd has entered into a sales agreement with Kerself SpA. Under the terms of the agreement, Trina Solar will supply Kerself Group with approximately 73 MW of PV modules, with shipment deliveries of 23 MW expected in 4Q 2009 and 25 MW...

CTI BioForce 9000 technology exceeds performance expectations - CTI, process concepts and SRS engineering's first plant installation of CTI's new third generation biodiesel technology is a success.
September 30, 2009... Cavitation Technologies Inc (CTI) is pleased to announce Producer's Choice Soy Energy, Moberly, MO biodiesel production plant is performing above expectations. CTI's BioForce 9000 nano-cavitation biodiesel reactor is a unique low cost single...

BioCryst provides update regarding peramivir for influenza.
September 30, 2009... BioCryst Pharmaceuticals Inc (BioCryst) has delivered a written response to the request for proposal (RFP) announced on 21 Sep 2009 from the US Department of Health & Human Services (HHS) for the supply of intravenous (iv) peramivir for the...

Epigentek develops a new method of measuring global DNA methylation.
September 30, 2009... Epigentek Group Inc released the SuperSense Methylated DNA Quantification Kit to complete its line of methylated DNA quantification products. The SuperSense kit fluorometrically measures global DNA methylation shifts. This new tool complements...

Superior efficacy-dose ratio for Lantus over detemir.
September 30, 2009... Sanofi-aventis announced results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The study was presented...

MarketsandMarkets: Global neurostimulation market worth $10.2 bn by 2014.
September 30, 2009... According to a new market research report, 'Neurostimulation Market', published by MarketsandMarkets, the global market for neurostimulation products is expected to be worth $3.6 bn in 2009, and expected to reach $10.2 bn by 2014, driven by the...

Quest PharmaTech acquires late-stage immunotherapeutic antibody pipeline.
September 30, 2009... Quest PharmaTech Inc (Quest) has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc (Paladin). The pipeline of product candidates consists of five monoclonal antibodies targeting certain tumour antigens that...

EMD Serono submits application for Cladribine tablets as a potential oral short-course multiple sclerosis therapy in the US.
September 30, 2009... EMD Serono Inc announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing...

Sagent Pharmaceuticals launches Vinorelbine injection, USP.
September 30, 2009... Sagent Pharmaceuticals Inc announced on 30 Sep 2009 that it has launched vinorelbine injection, USP, an anti-mitotic chemotherapy drug. According to IMS, 2008 sales of vinorelbine injection, USP in the US approximated $17 M. Sagent will begin...

Intarcia Therapeutics Inc presents positive results of ITCA 650 Phase Ib study in Type 2 diabetes at the European Association for the Study of Diabetes Conference.
September 30, 2009... Intarcia Therapeutics Inc presented final results from its Phase Ib clinical study of ITCA 650 (Duros continuous delivery of exenatide) for the treatment of type 2 diabetes at the Annual Conference of the European Association for the Study of...

Alexza to raise $19.7 M in private placement.
September 30, 2009... Alexza Pharmaceuticals Inc (Alexza) has entered into a definitive agreement with various institutional investors to raise $19.7 M in a private placement of its common stock. Under the terms of the financing, Alexza is expected to sell...

MarketsandMarkets: Global home health care market worth $159.6 bn by 2014.
September 30, 2009... According to a new healthcare market research report Global Home Care and Self Care Market (2009 2014), published by MarketsandMarkets, in 2009, the entire home healthcare market covered under the report is estimated to be approximately $159.6...

Hospira acquires worldwide rights to biogeneric version of filgrastim and manufacturing facility from Pliva.
September 30, 2009... Hospira Inc announced the acquisition of worldwide rights to a biogeneric version of filgrastim and an affiliated European manufacturing facility from Pliva Hrvatska doo (Pliva) (Zagreb, Croatia), a move that will help extend Hospira's reach and...

InteKrin Therapeutics presents positive INT131 Phase IIb results at the 45th Annual European Association for the Study of Diabetes Meeting.
September 30, 2009... InteKrin Therapeutics Inc (InteKrin) announced positive results for INT131 in a 24 week Phase IIb study at the 45th European Association for the Study of Diabetes Meeting in Vienna, Austria. In this study INT131 demonstrated a superior side...

Sinovac obtains second order of H1N1 vaccine from Chinese central government.
September 30, 2009... Sinovac Biotech Ltd (Sinovac) announced that Sinovac has received its second purchase order for its H1N1 vaccine, PANFLU.1, from the Ministry of Industry and Information Technology of the People's Republic of China for the national stockpiling...

Ganeden Biotech announces grants for early investigators to research probiotic GanedenBC30.
September 30, 2009... Ganeden Biotech Inc, makers of the patented probiotic strain GanedenBC30 announced two grants for early investigators. Grants focus on researching the effects of GanedenBC30 on human immune cells. Previous studies have demonstrated the ability...

Orexigen Therapeutics Phase IIb trial for Empatic meets primary efficacy endpoint demonstrating significantly greater weight loss versus comparators in obese patients.
September 30, 2009... Orexigen Therapeutics Inc announced that its 24-week, Phase IIb trial for Empatic (bupropion SR/zonisamide SR), the company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by...

Amicus Therapeutics announces plan to initiate Phase I study of AT2220 for Pompe Disease.
September 30, 2009... Amicus Therapeutics plans to initiate a Phase I study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease. The primary objective of this study is to evaluate the pharmacokinetics of...

Valeant to acquire major Australian skincare brands.
September 30, 2009... Valeant Pharmaceuticals International (Valeant) has agreed to acquire Private Formula International Holdings Pty Limited, a leading skincare company. Through its acquisition of Private Formula International, Valeant is acquiring global rights to...

MacuSight provides clinical development update for Perceiva.
September 30, 2009... MacuSight provided a clinical development update for Perceiva, the company's proprietary ocular sirolimus product. The company has completed patient enrolment in four ongoing Phase II clinical trials of Perceiva and plans to announce data from...

GenVec receives National Cancer Institute grant to expand cancer programme.
September 30, 2009... GenVec Inc has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer....

Article published in Expert Opinion on Biological Therapy evaluates StemEx (carlecortemcel-l) for leukaemia and lymphoma.
September 30, 2009... Gamida Cell announced the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as StemEx, as a therapy for blood cancers such as leukaemia and lymphoma. The article, carlecortemcel-l, an ex vivo...